Arbeitsgruppe Ösophagus-/Magen-Karzinome - Studien
Stadium II/III Adenokarzinom des Magens oder gastroösophagealen Übergangs – neoadjuvante/ perioperative Therapie

AIO-Studie  

zur Studie

AIO-STO-0215: Effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of AIO/CAO-V/CAOGI  (RENAISSANCE / FLOT5)

Weitere Informationen zur Studie finden Sie hier!
Pressemitteilung zur RENAISSANCE-Studie mehr 
  ---in Rekrutierung; weitere Zentren nur auf Anfrage ---

AIO-Studie
www.clinicaltrials.gov
zur Studie

AIO-STO-0317: A randomized, open-label Phase II efficacy and safety study of Atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction (MO30039) - DANTE-Trial
  ---in Rekrutierung---

AIO-assoziierte Studie Für weitere Zentren offen
zur Studie

AIO-STO-0319/ass: Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Typ II/III adenocarcinoma - A phase III trial of the AIO/CAOGI/ACO (FLOT-9)
  ---in Vorbereitung---
Locally advanced, resectable adenocarcinoma of the esophagogastric junction

AIO-Studie Für weitere Zentren offen
  zur Studie

AIO-STO-0118: Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) - A randomized phase III joint study of the AIO, ARO and DGAV (RACE-trial)
  ---in Vorbereitung---
Lokal fortgeschrittenes oder metastasiertes Adenokarzinom des Magens oder gastroösophagealen Übergangs - palliative Therapie, 1st-line

AIO-Studie Für weitere Zentren offen
www.clinicaltrials.gov zur Studie

AIO-STO-0217: Ipilimumab or FOLFOX in combination with Nivolumab and Trastuzumab in previously untreated HER2 positive locally advanced or metastastic EsophagoGastric Adenocarcinoma
The randomized phase 2 INTEGA trial.
  ---in Rekrutierung---

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-STO-0417: Modified FOLFOX plus/minus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction - The randomized phase 2 MOONLIGHT trial. (A study of the AIO)
  ---geschlossen, erneute Öffnung der Studie nach Amendment geplant---
Lokal fortgeschrittenes oder metastasiertes Adenokarzinom des Magens oder gastroösophagealen Übergangs - palliative Therapie, 2nd-line

AIO-Studie Für weitere Zentren offen www.clinicaltrials.gov zur Studie

AIO-STO-0415: A randomized, open label phase II trial of Irinotecan / Folinic Acid / 5-FU plus Ramucirumab versus Paclitaxel plus Ramucirumab in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy (RAMIRIS)
  ---in Rekrutierung---

AIO-assoziierte Studie Für weitere Zentren offen  
zur Studie

AIO-STO-0419/ass: A study of Ramucirumab beyond progression plus TAS- 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy - RE- ExPEL
  ---in Vorbereitung ---
Metastasiertes/fortgeschrittenes Magenkarzinom, Second-Line (2nd Line)

AIO-Studie Für weitere Zentren offen
www.clinicaltrialsregister.eu zur Studie

AIO-STO-0218: Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO (The RAP Trial)
  ---in Rekrutierung---
Plattenepithelkarzinom des Ösophagus, Zweitlinientherapie

AIO-assoziierte Studie Für weitere Zentren offen www.clinicaltrials.gov zur Studie

AIO-STO-0216/ass: A randomized, multicenter open label phase II trial of Paclitaxel + Ramucirumab versus Paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy with Fluoropyrimidine and Platinum-based drugs – The RAMOS study
  ---in Rekrutierung---

AIO-Studie
www.clinicaltrials.gov zur Studie

AIO-STO-0117: A multicenteR open-label phase II triAl to evaluate NivoluMab and Ipilimumab fOr 2nd line therapy in elderly patieNts with advanced esophageal squamous cell cAncer [RAMONA]
  ---in Rekrutierung---
Register: Hepatozelluläres Karzinom / Gallengangskarzinom / Gallenblasenkarzinom / Pankreaskarzinom /  Magen- und Speiseröhrenkarzinom – palliativ, first line

AIO-assoziierte Studie
zum Platon-Netzwerk zur Studie

AIO-HEP/STO-0219/ass: Platform for Analyzing Targetable Tumor Mutations - PLATON
  ---in Vorbereitung ---
LETZTE AKTUALISIERUNG DIESER SEITE AM: 01.05.2020